This pilot study is a randomized controlled intent-to-treat (ITT) clinical trial. Potential participants will be recruited from the University of Cincinnati Medical Center (UCMC) Emergency Department (ED) where they are being treated for an OOD. Approximately eighty eligible participants will be randomized in a 1:1 ratio to the control condition (Information and NARCAN® (naloxone) Nasal Spray kit) or to the experimental condition (TTIP-PRO in addition to the elements provided in the control condition). All participants will complete a follow-up phone call approximately 3-weeks post-randomization, during which process measures will be completed, and in-person visits at approximately 3, 6-, and 12-months following enrollment.